Company Overview of Aerial BioPharma LLC
Aerial BioPharma LLC, a biopharmaceutical company, engages in drug development for central nervous system. The company focuses on developing biologics and small molecules for conditions that are affected by processes in the central nervous system. Aerial BioPharma LLC was founded in 2011 and is based in Morrisville, North Carolina.
9001 Aerial Center Parkway
Aerial Center Executive Park
Morrisville, NC 27703
Founded in 2011
Key Executives for Aerial BioPharma LLC
Co-Founder and Chief Executive Officer
Co-Founder and Executive Vice President of Drug Development
Acting Chief Financial Officer
Senior Director of Chemistry and Manufacturing
Compensation as of Fiscal Year 2014.
Aerial BioPharma LLC Key Developments
Jazz Pharmaceuticals Announces Acquisition from Aerial BioPharma LLC of Rights to Late Stage Investigational Compound for Excessive Daytime Sleepiness
Jan 13 14
Jazz Pharmaceuticals plc and Aerial BioPharma, LLC announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the agreement, a subsidiary of Jazz Pharmaceuticals has acquired worldwide development, manufacturing and commercial rights to ADX-N05, other than in certain countries in Asia where SK Biopharmaceuticals Co. Ltd. (SK) retains rights. Under the agreement, Aerial will receive an upfront payment of $125 million. Aerial and SK are eligible to receive milestone payments based on development, regulatory and sales milestones and tiered royalties based on potential future sales.
Aerial BioPharma LLC Presents at 2013 BIO International Convention, Apr-23-2013 03:00 PM
Apr 18 13
Aerial BioPharma LLC Presents at 2013 BIO International Convention, Apr-23-2013 03:00 PM. Venue: McCormick Place - Chicago Bulls Room, 2301 S. Lake Shore Drive, Chicago, IL 60616, United States.
Aerial BioPharma LLC Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development
Aug 29 12
Aerial BioPharma LLC has received orphan drug designation for its narcolepsy drug in development. The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan for ARL-N05 for the treatment of narcolepsy. In the United States, the prevalence of narcolepsy is estimated to be less than 200,000 qualifying as an orphan disease. The narcolepsy treatment will begin a Phase IIb clinical trial in September with results expected in mid-2013. The news from the FDA follows the successful completion of a Phase IIa study where N05 demonstrated highly statistically significant results on the primary and secondary efficacy endpoints in patients with narcolepsy.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries